BookMotohiro Kato, editor.
Summary: This book discusses key aspects of childhood acute lymphoblastic leukemia (ALL), presenting the latest research on the biology and treatment of the disease and related issues. The cure rate for ALL has improved dramatically due to advances such as supportive care, treatment stratification based on relapse risk, and the optimization of treatment regimens. Gathering contributions by eminent scholars Pediatric Acute Lymphoblastic Leukemia is a valuable resource for pediatric hematologists as well as for medical students, interns, residents and fellows. It not only offers comprehensive insights, but also provides a springboard for future research.
Contents:
Intro; Preface; Contents; Part I: Epidemiology and Diagnosis of Pediatric ALL;
Chapter 1: Overview; 1.1 Introduction; 1.2 Symptoms and Diagnosis; 1.3 Treatment; 1.4 Future Directions; References;
Chapter 2: Genetic Alterations of Pediatric Acute Lymphoblastic Leukemia; 2.1 B Precursor ALL with Recurrent Fusion or Chromosomal Abnormality; 2.1.1 KMT2A Rearrangement; 2.1.2 ETV6-RUNX1 and High Hyperdiploid; 2.1.3 TCF3 Rearrangement; 2.1.4 Hypodiploid; 2.1.5 BCR-ABL1; 2.2 New Subtype of B-ALL; 2.2.1 IKZF1 Deletion, CRLF2 Deregulation, and Ph-Like ALL; 2.2.2 iAMP21 2.2.3 MEF2D and ZNF384 Rearranged ALL2.2.4 DUX4 Rearranged ALL; 2.2.5 Others; 2.3 Genetic Alterations of T-ALL; 2.4 Genetic Alterations of Acute Leukemia Ambiguous Lineage; 2.5 Genetic Alterations of Relapsed B-ALL; 2.6 Clinical Implications of Genetic Studies; References;
Chapter 3: Germline Biology of Pediatric ALL; 3.1 Importance of Germline Variants in Leukemia Biology; 3.2 Germline Biology for Drug Response; 3.2.1 Pharmacogenomics of Adverse Events; 3.3 Germline Biology for Leukemogenesis; 3.3.1 Leukemia Predisposing Syndrome; 3.3.2 Leukemia Predisposing in Non-syndromic ALL; References
Chapter 4: Immunophenotype of Pediatric ALL4.1 Diagnostic Criteria of Pediatric ALL According to Immunophenotyping; 4.2 Immunophenotyping of B-Lineage ALL; 4.3 Immunophenotyping of T-Lineage ALL; 4.4 Relationship Between Immunophenotyping and Cytogenetic Abnormalities; References;
Chapter 5: MRD in Pediatric ALL; 5.1 Introduction; 5.2 Detection Methods of Minimal Residual Disease; 5.2.1 PCR-Based MRD Detection; 5.2.2 FCM-Based MRD Detection; 5.3 Clinical Impact of MRD; 5.4 Future of Minimal Residual Disease Detection; References; Part II: Treatment of Pediatric ALL
Chapter 6: B-Cell Precursor ALL6.1 Risk Stratification of B-Cell Precursor ALL; 6.2 Treatment Backbone of B-Cell Precursor ALL; 6.2.1 Induction Therapy; 6.2.2 Consolidation Therapy; 6.2.3 Maintenance Therapy; 6.2.4 CNS Directed Therapy; 6.2.5 Immunotherapy; References;
Chapter 7: Pediatric T-Cell Acute Lymphobastic Leukemia; 7.1 Epidemiology; 7.2 Diagnosis; 7.3 Clinical and Biological Characteristics; 7.4 Treatment; 7.5 Prognostic Factors; 7.6 Future Directions; 7.7 Conclusion; References;
Chapter 8: Mature B-Cell Acute Lymphoblastic Leukemia; 8.1 Epidemiology; 8.2 Pathology/Biology 8.3 Clinical Presentation8.4 Treatment; 8.4.1 Standard Treatments; 8.4.2 Relapsed or Refractory Disease; References;
Chapter 9: Infant ALL; 9.1 Introduction; 9.2 Risk Stratifications in Infant ALL; 9.3 Treatment of Infant MLL-r ALL; 9.3.1 Chemotherapy; 9.3.2 Hematopoietic Stem Cell Transplantation; 9.3.3 Novel Therapies; 9.3.3.1 Nucleoside Analogues; 9.3.3.2 FLT3 Inhibitors; 9.3.3.3 Epigenetic Agents; 9.3.3.4 BCL-2 Inhibitors; 9.3.3.5 Immunotherapies; 9.4 Treatment of Infant MLL-g ALL; 9.5 Treatment of Relapsed Infant ALL; 9.6 Acute and Late Toxicities on Infant ALL Treatment; References